Research Papers:

Sox9 is required for prostate development and prostate cancer initiation

Zhenhua Huang _, Paula J. Hurley, Brian W. Simons, Luigi Marchionni, David M. Berman, Ashley E. Ross and Edward M. Schaeffer

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2012; 3:651-663. https://doi.org/10.18632/oncotarget.531

Metrics: PDF 3460 views  |   HTML 3779 views  |   ?  


Zhenhua Huang1,2,3, Paula J Hurley1, Brian W Simons1,2,3, Luigi Marchionni2,3, David M Berman1,2,3, Ashley E Ross1 and Edward M Schaeffer1,2,3

1 Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

2 Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

3 Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

Received: June 26, 2012; Accepted: June 30, 2012; Published: July 2, 2012;

Keywords: Sox9, prostate, development, cancer, initiation


Edward M Schaeffer, email:


Prostate cancer is one of the most common malignancies and the second leading cause of death from cancer in men. The molecular mechanisms driving prostate carcinogenesis are complex; with several lines of evidence suggesting that the re-expression of conserved developmental programs plays a key role. In this study, we used conditional gene targeting and organ grafting, to describe conserved roles for the transcription factor Sox9 in the initiation of both prostate organogenesis and prostate carcinogenesis in murine models. Abrogation of Sox9 expression prior to the initiation of androgen signaling blocks the initiation of prostate development. Similarly, Sox9 deletion in two genetic models of prostate cancer (TRAMP and Hi-Myc) prevented cancer initiation. Expression profiling of Sox9-null prostate epithelial cells revealed that the role of Sox9 in the initiation of prostate development may relate to its regulation of multiple cytokeratins and cell adherence/polarity. Due to its essential role in cancer initiation, manipulation of Sox9 targets in at-risk men may prove useful in the chemoprevention of prostate cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 531